Curium Pharma

Curium Pharma is a global leader in nuclear medicine and radiopharmaceutical manufacturing, supplying vital diagnostic and therapeutic solutions to healthcare providers worldwide. The company develops, manufactures, and distributes radioactive tracers, generators, cold kits, and hot products used in molecular imaging and targeted radioligand therapies. Serving public and private hospitals, radiopharmacies, and imaging centers in over 60 countries, Curium Pharma enables early diagnosis and treatment of oncology, cardiology, neurology, and bone diseases. Operating an extensive vertically-integrated network with manufacturing sites in Maryland Heights, Noblesville, Petten, and Saclay, the radiopharmaceuticals supplier ensures stable isotope delivery to over 14 million patients annually. As a trusted radiopharmaceutical distributor and manufacturer, the group specializes in PET and SPECT nuclear imaging technologies, including F18 and Tc99m isotopes. The company continues to advance cancer care through ongoing clinical trials and innovative radiodiagnostics targeting neuroendocrine tumors and prostate cancer. With headquarters in Boston and Paris, Curium Pharma provides comprehensive customer support, drug safety monitoring, and reliable medical logistics across global healthcare markets.